Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 0.75% 134.40 134.20 134.60 135.00 133.40 133.40 2,125,288 16:29:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 186.1 17.5 7.7 1,428

Ip Share Discussion Threads

Showing 2001 to 2024 of 2325 messages
Chat Pages: Latest  81  80  79  78  77  76  75  74  73  72  71  70  Older
DateSubjectAuthorDiscuss
16/12/2020
16:44
when will it ipo is all i want to know?
edwardt
15/12/2020
14:57
Oxford Nanopore Technologies Ltd - Oxford Nanopore and SourceBio announce commercial partnership for UK COVID-19 testing service 15 Dec 2020 Oxford Nanopore’s rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities Oxford Nanopore Technologies Limited (“Oxford Nanopore”), a leading next generation DNA/RNA sequencing technology company and SourceBio International plc (“SourceBio221;), an international provider of integrated state of the art laboratory services and products, announce a strategic commercial partnership to offer a commercially available COVID-19 testing solution to corporate customers wishing to provide high quality testing to their employees or other stakeholders, at scale. The test will also be offered to consumers. If you are a company or organization wishing to deploy testing for your teams, please contact us using this form: hxxps://register.nanoporetech.com/lampore-source-bioscience. If you are a private individual wishing to have a COVID test, please use this link hxxps://coviduk.sourcebioscience.com. Oxford Nanopore’s CE-marked LamPORE COVID-19 assay, for the detection of SARS-CoV-2, will be used at SourceBio’s state-of-the-art ISO15189 accredited laboratory facility in Nottingham to offer a large-scale COVID-19 diagnostic testing service. LamPORE is a new generation of test; LamPORE COVID-19 is specifically designed to detect SARS-CoV-2, the virus that causes COVID-19. LamPORE is rapid and highly scalable, allowing for high performance test deployment in both high-throughput, traditional laboratory settings as well smaller, more local lab environments – addressing the need for rapid, routine testing of large numbers of people. LamPORE has been shown to have sensitivity of 99.1% and specificity of 99.6%. In this instance, the LamPORE COVID-19 test is performed from oropharyngeal and nasopharyngeal swabs which are sent to SourceBio for assessment and can return a positive or negative result within 24 hours of the laboratory receiving the sample. LamPORE also includes a built-in human actin control, which enables operators to discriminate between negative results due to sample collection errors and negative results due to the absence of SARS-CoV-2 infection. With options for using LamPORE in a fixed laboratory, or even in mobile community testing, the service is expected to broaden access to rapid, high quality testing to support people to return to work, to visit friends and relatives safely, and potentially assist with international travel where testing is accepted or required, given that LamPORE is a high-accuracy molecular test. The COVID-19 testing service using LamPORE will be offered as an additional service by SourceBio to complement its existing COVID-19 PCR Testing services which is currently used by the NHS, Private Healthcare providers and other commercial customers. Gordon Sanghera, Co-founder and Chief Executive Officer at Oxford Nanopore Technologies Limited, said: “We are delighted that high quality COVID-19 testing with LamPORE will now be available privately in the UK through the high-quality labs of Source Bioscience. As the UK rolls out a vaccine programme, the importance of safeguarding workforces and customers, as well as friends and family, remains a priority for many businesses and individuals. We’re committed to being part of the solution in the UK public and private sectors, and pleased that our technology can support a transition back to work, leisure and family life.” Jay LeCoque, Executive Chairman of SourceBio International plc, said: “The commercial relationship that we have developed with Oxford Nanopore is a valuable partnership that delivers essential testing technology and a high-quality service offering, at a crucial time in the worldwide effort to combat and manage the further spread of Coronavirus. This alliance effectively creates a ‘total solutions approach’ for both company’s offerings by combining Oxford Nanopore’s leading LamPORE COVID-19 test with our UKAS accredited laboratory services. this combination allows both companies to provide clients with a high quality, highly scalable and highly professional product and a fully accredited laboratory services capability.” “The UK Government has minimum standards for private sector providers of COVID-19 testing and we are delighted to have been awarded full UKAS ISO15189 status for our COVID testing. Very few commercial institutions have received this standard and it is a mandatory requirement from next summer 2021. This underscores the high standard of our accredited testing services and provides us with a significant advantage in the market.” LamPORE is a new generation of COVID-19 test that uses Oxford Nanopore’s sequencing technology. Beyond testing for COVID-19, the nanopore platform is being explored by the scientific community for a broader range of analyses, including detection of multiple respiratory pathogens, characterization of drug-resistant bacteria, analysis of cancer samples and tissue matching for transplantation. Oxford Nanopore Technologies Ltd - Oxford Nanopore and SourceBio announce commercial partnership for UK COVID-19 testing service 15 Dec 2020 Oxford Nanopore’s rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities Oxford Nanopore Technologies Limited (“Oxford Nanopore”), a leading next generation DNA/RNA sequencing technology company and SourceBio International plc (“SourceBio221;), an international provider of integrated state of the art laboratory services and products, announce a strategic commercial partnership to offer a commercially available COVID-19 testing solution to corporate customers wishing to provide high quality testing to their employees or other stakeholders, at scale. The test will also be offered to consumers. If you are a company or organization wishing to deploy testing for your teams, please contact us using this form: hxxps://register.nanoporetech.com/lampore-source-bioscience. If you are a private individual wishing to have a COVID test, please use this link hxxps://coviduk.sourcebioscience.com. Oxford Nanopore’s CE-marked LamPORE COVID-19 assay, for the detection of SARS-CoV-2, will be used at SourceBio’s state-of-the-art ISO15189 accredited laboratory facility in Nottingham to offer a large-scale COVID-19 diagnostic testing service. LamPORE is a new generation of test; LamPORE COVID-19 is specifically designed to detect SARS-CoV-2, the virus that causes COVID-19. LamPORE is rapid and highly scalable, allowing for high performance test deployment in both high-throughput, traditional laboratory settings as well smaller, more local lab environments – addressing the need for rapid, routine testing of large numbers of people. LamPORE has been shown to have sensitivity of 99.1% and specificity of 99.6%. In this instance, the LamPORE COVID-19 test is performed from oropharyngeal and nasopharyngeal swabs which are sent to SourceBio for assessment and can return a positive or negative result within 24 hours of the laboratory receiving the sample. LamPORE also includes a built-in human actin control, which enables operators to discriminate between negative results due to sample collection errors and negative results due to the absence of SARS-CoV-2 infection. With options for using LamPORE in a fixed laboratory, or even in mobile community testing, the service is expected to broaden access to rapid, high quality testing to support people to return to work, to visit friends and relatives safely, and potentially assist with international travel where testing is accepted or required, given that LamPORE is a high-accuracy molecular test. The COVID-19 testing service using LamPORE will be offered as an additional service by SourceBio to complement its existing COVID-19 PCR Testing services which is currently used by the NHS, Private Healthcare providers and other commercial customers. Gordon Sanghera, Co-founder and Chief Executive Officer at Oxford Nanopore Technologies Limited, said: “We are delighted that high quality COVID-19 testing with LamPORE will now be available privately in the UK through the high-quality labs of Source Bioscience. As the UK rolls out a vaccine programme, the importance of safeguarding workforces and customers, as well as friends and family, remains a priority for many businesses and individuals. We’re committed to being part of the solution in the UK public and private sectors, and pleased that our technology can support a transition back to work, leisure and family life.” Jay LeCoque, Executive Chairman of SourceBio International plc, said: “The commercial relationship that we have developed with Oxford Nanopore is a valuable partnership that delivers essential testing technology and a high-quality service offering, at a crucial time in the worldwide effort to combat and manage the further spread of Coronavirus. This alliance effectively creates a ‘total solutions approach’ for both company’s offerings by combining Oxford Nanopore’s leading LamPORE COVID-19 test with our UKAS accredited laboratory services. this combination allows both companies to provide clients with a high quality, highly scalable and highly professional product and a fully accredited laboratory services capability.” “The UK Government has minimum standards for private sector providers of COVID-19 testing and we are delighted to have been awarded full UKAS ISO15189 status for our COVID testing. Very few commercial institutions have received this standard and it is a mandatory requirement from next summer 2021. This underscores the high standard of our accredited testing services and provides us with a significant advantage in the market.” LamPORE is a new generation of COVID-19 test that uses Oxford Nanopore’s sequencing technology. Beyond testing for COVID-19, the nanopore platform is being explored by the scientific community for a broader range of analyses, including detection of multiple respiratory pathogens, characterization of drug-resistant bacteria, analysis of cancer samples and tissue matching for transplantation. SourceBio International plc ticker = SBI
bamboo2
14/12/2020
12:13
Https://www.cshl.edu/the-worlds-first-dna-tricorder-in-your-pocket/ Cold Spring Harbor Laboratory (CSHL) scientists developed the world’s first mobile genome sequence analyzer, a new iPhone app called iGenomics. By pairing an iPhone with a handheld DNA sequencer, users can create a mobile genetics laboratory, reminiscent of the “tricorder” featured in Star Trek. The iGenomics app runs entirely on the iOS device, reducing the need for laptops or large equipment in the field, which is useful for pandemic and ecology workers. Aspyn Palatnick programmed iGenomics in CSHL Adjunct Associate Professor Michael Schatz‘s laboratory, over a period of eight years, starting when he was a 14-year-old high school intern. The iPhone app was developed to complement the tiny DNA sequencing devices being made by Oxford Nanopore. Palatnick, now a software engineer at Facebook, was already experienced at building iPhone apps when joining the Schatz laboratory. He and Schatz realized that....
bamboo2
10/12/2020
15:19
Still to find out what they do with their fire power. Can't help thinking they have something lined up. Some strange new tech in Quantum or Fusion that will need big support.
p1nkfish
10/12/2020
14:41
A year ago Ceres Power was IPO's third biggest investment, and its second most successful after Oxford Nanopore. In July IPO placed the majority of its stake at £5.85 per Ceres share. Since then the Ceres share price has almost doubled to around £11. I would really like to believe that IPO will succeed as a profitable incubator for UK university spinouts. But the premature sale of Ceres makes me wonder. Remember the old investment adage 'run your winners and cut your losers'.
bottomfisher
08/12/2020
08:58
Mas, I have been dribbling some buys in at around 92! I can't help thinking that Invesco, with their financial reporting year end looming in a few weeks, are going to be sorely tempted to unload quite a few more to free up some cash. ps. I am targeting approx 89.5 and keeping cash available
bamboo2
08/12/2020
08:36
iGenomics: Comprehensive DNA sequence analysis on your Smartphone Https://academic.oup.com/gigascience/article/9/12/giaa138/6025149 DNA sequencing technology has made tremendous progress over the past 30 years [1]. The earliest automated approaches, beginning with the capillary-based Sanger sequencing devices in the 1980s, were large bench-top instruments requiring extensive sequencing facilities to prepare and sequence the DNA. In the 2000s, high-throughput second-generation sequencing instruments advanced the field with more compact and simpler designs. However, these advances have been limited in their reach because they are not readily accessible by most individual laboratories and citizen scientists. Most substantially, the most widely used alignment and analysis tools are not targeting citizen scientists and require expert knowledge on using the command line to install several software packages, run the tools, and understand a variety of file formats. Within the past few years, Oxford Nanopore Technologies (ONT, Oxford, UK) has introduced a small inexpensive hand-held sequencing instrument that has made it possible to perform genomics experiments with minimal facilities and in essentially any environment. Because of its small size, Nanopore sequencing has been used in several environments that would be unthinkable for alternative instruments as diverse as monitoring the Ebola outbreaks in remote areas of Africa [2], monitoring Zika outbreaks in South America [3], exploring reptile specimens in the rainforest [4], and even on the International Space Station [5]. Nanopore sequencing has also played an important role in monitoring the transmission of SARS-COVID-19 around the world [6–8]. Nanopore sequencing technology works by measuring the change in ionic current as a DNA molecule is passed through a nanopore [1]. The DNA molecules are typically a few hundred to tens of thousands of nucleotides long, and the longest reported read has exceeded 2 million nucleotides [9]. Once sequenced, the raw signal data are base-called into nucleotide strings called reads [10], which are typically stored in fastq format and saved for further processing, especially read alignment and variant analysis. Several algorithms are available for this analysis. Modern aligners, such as Bowtie [11] or BWA-MEM [12], often use the Burrows-Wheeler transform (BWT) [13] and the closely related FM-index [14] as their core indexing data structure. These new approaches are suited to large datasets because of their compact space requirements and fast alignment times. After alignment, variant-calling platforms, such as SAMtools [15] or GATK [16], systematically scan the alignments to find well-supported variants in the sample using a statistical model to distinguish homozygous from heterozygous variants and rule out spurious sequencing errors. After this automated variant identification, high-priority variants are also often manually inspected using IGV [17] and other genome browsers to review the evidence for the variant calls and further rule out false-positive calls. The standard approach for analyzing reads is to align the reads to a reference genome on high-end laptops, servers, or even supercomputers. While this is feasible for those with access to these technologies, these requirements may be out of reach for many researchers and citizen scientists. Instead, iGenomics just requires the sequenced reads, which can be loaded from the phone itself, the internet, or elsewhere, and can allow anyone to perform sequence analysis and mutation identification. As with other mobile applications (e.g., web browsing, e-mail, social media), iGenomics can be used in a variety of settings where it would be awkward to use a larger laptop, and many users will also prefer the more intuitive user interface. Furthermore, there are many important scenarios where analyzing these data without high-end computing hardware is desirable, especially in remote environments. Interestingly, current iOS devices, including both iPads and iPhones, have significant computing resources, with clock speeds and onboard RAM approaching that of high-end laptop computers. That said, no stand-alone genomics analysis software is currently available for iOS devices. Addressing this critical gap, we have developed iGenomics, an iOS application that allows anyone to easily align and analyze DNA sequences in a mobile environment. iGenomics uses the same high-performance algorithms for read alignment and variant calling as mainstream software, although iGenomics marks the first time these algorithms have been implemented in a mobile iOS environment. Additionally, using the advanced user interface features available in iOS, iGenomics allows for interactive visualization and inspection of the read alignments and variant calls, and contains additional features for reviewing critical mutations of interest. For example, iGenomics comes bundled with a listing of critical mutations in the influenza A virus that indicate which antiviral agents are most likely to be ineffective [18]. Owing to the lower amount of processing power in mobile devices compared with high-end desktop computers or servers, iGenomics is limited in the size of the genome that can be processed. However, the implementations in iGenomics have been rigorously tested through direct comparisons with the BWA-MEM/SAMtools framework for alignment and variant calling for viral and microbial genomes. All alignment and analysis algorithms used by iGenomics have been tested on both real and simulated datasets to ensure consistent speed, accuracy, and reliability of both alignments and variant calls. Consequently, iGenomics is leading the shift of DNA analysis software and sequencing tools towards mobile devices and marks a great leap forward towards widespread DNA analysis by non-bioinformatician students, researchers, and citizen scientists. Furthermore, iGenomics is available open source to facilitate mobile genomics technology research and, in turn, accelerate the speed at which this technology is developed.
bamboo2
08/12/2020
08:15
"Assuming we are entering a new trading range starting at 85, the upper end should be around 93-94." Well bamboo2, we're there this morning. Will it break through to the upside or will it become a new resistance level!
masurenguy
05/12/2020
09:14
Hi Wp, Yes I think you are right. There will come a point where selling pressure is lowered. It'll be interesting to see over the next few weeks if price stays in the trading range, as it has done before. I listed these ranges in a previous post. If it matches those previously, the current one ends around 13/1/2021, and price should move to a new range then. ============================================= From 18/11/2020 Based on previous consolidation zones, the stock was due a rerate to a higher trading range. Each zone is 41-42 sessions long. Since the uptrend began the ranges are 11, 9.6, 7.6, 8.1 Assuming we are entering a new trading range starting at 85, the upper end should be around 93-94. ============================================ gla
bamboo2
05/12/2020
02:09
BB, I did similar with AAF which has worked well but I reckon there's more sticky money coming into the market now so there may be less volatility on the way up.
wetpantz
04/12/2020
16:49
Wetpantz, I attempting to trade the uptrend and am planning to buy back in as soon as possible. My holding fluctuates from 10-80k, and I normally average in and out in 10-20k lots. This has ben a superb share to trade this year. I must have done 100's of trades. My broker and the stamp duty collector have also done very well! :-)
bamboo2
04/12/2020
16:32
I'm still holding on (25% of portfolio). Now that invesco and lansdowne largely sold out overhang is gone and the trend up since April has been v consistent. Short sellers got out ages ago and IPO seems to have left the Woodford debacle well and truly in the past. Will only consider selling once NANOPORE goes public.
wetpantz
04/12/2020
14:50
p1nk, thanks. No worries. Lansdowne below 5% from 1/12/2020 Have sold most of mine for now on the rise to 94 as think this is near the top of the current trading range. Hope I can buy back a bot lower down, rather than have to chase up! gla
bamboo2
03/12/2020
21:38
bamboo, I don 't remember their routines for notifying on 2%+ holders.
p1nkfish
03/12/2020
20:23
Good vibrations as 8powerUK raises £2m growth capital to underpin expansion across the UK and Europe. The round includes follow-on investment from IPGroupplc... Https://www.8power.com/ ABOUT 8POWER 8power is a Cambridge, UK based innovative technology company specialising in self-powered wireless sensor solutions for industrial plant applications. We are enabling machine condition monitoring at lower cost and easy installation for water/waste treatment, manufacturing industries and oil and gas industries. The 8power solution is based on ground breaking, patented technology from the University of Cambridge. 8POWER SOLUTION 8power’s technology provides a proactive, early warning and remote monitoring solution for a range of industrial plant equipment. This offers organisations a self-powered, scalable solution to monitor plant equipment installed in unmanned, remote or difficult to reach locations. 8power uses energy harvested from the assets environment to provide an easy to install, efficient and consistent way of monitoring different sizes and types of industrial asset. VIBRATION ENERGY HARVESTING Our patented Vibration Energy Harvester (VEH) technology provides self-powered wireless sensors that eliminate battery changes or wiring of power supplies. This dramatically lowers the cost of installation and operation over the life of an asset. VEH provides a sustainable and scalable solution to address the sensing needs of a range of equipment types.
bamboo2
03/12/2020
20:09
B/f, have a look at the last report to get more detail on the overheads and staff numbers. Some of the smaller companies have their employees and overheads lumped in with IPO's. Page 23 of the IP Group half year report Included within the Group’s administrative expenses are costs in respect of a small number of other portfolio companies. Typically, the Group owns a non-controlling interest in its portfolio companies; however, in certain circumstances the Group takes a controlling stake and hence consolidates the results of a portfolio company into the Group’s financial statements. The administrative expenses included in the Group’s results for such companies primarily comprise staff costs, R&D and other operating expenses. These costs included consolidated costs in respect of MOBILion Systems, Inc., for the first half of 2019 until its deconsolidation on 1 July 2019
bamboo2
03/12/2020
17:06
p1nkfish, you've been holding here for quite a while, so I thought you would be a good person to ask. I have had quite a few emails with the co, and on a recent reply about rns holdings notices was told that there would be an end of year report for 2020 with an update on holders above 2%. Do you know, is this normally released at the end of December, or do we have to wait until March 2021 for the report, along with the final results?
bamboo2
03/12/2020
15:39
Draper tend to hold stuff that will surprise but not totally left field. Evolution, Graphcore. IPO has the real surprise potential where something comes along as another Ox Nano but in fusion or some other area.
p1nkfish
03/12/2020
15:38
B/f, I hold both and not a bad idea to do so. Fundamental science out of Uni with long term focus - IPO sort of field. EU focused digital and disruptive in short/med term is Draper. Not a lot of overlap. Both have a reason to be held. I also hold some MERC for the regional exposure up north. A sucker for start-ups.
p1nkfish
03/12/2020
15:29
B/f With the death of Woodford last year, IPGroup was in a situation where nearly 50% of the company was in the hands of forced sellers. That is why these shares were under 50p at one point. Additional downward valuation pressure was caused by crossholdings of IPgroups listed and unlisted p/f constituents by WIM, Invesco, and Lansdowne. This situation has been managed really well imo, and the worst looks to be behind us now. WIM is out of it. Invesco are below 10%. Lansdowne are closing one of their funds, and we are still waiting to find out what the plans are with the approx 9% they hold. At the end of the year there is a report that should give us all more clarity.
bamboo2
03/12/2020
15:09
Today's Artois announcement suggests there might be more value hidden in the lower reaches of IPO's portfolio than the market suspects. However, even after the recent rally, the IPO share price is still trading at a 17% discount to NAV, whilst Draper Esprit (GROW), a fast growing VC rival, trades at a 9% premium and seems to have no difficulty regularly placing £100m plus tranches of shares priced at close to NAV to fund its portfolio of high growth disruptive tech stocks. Interested in any thoughts on which vehicle might make the better long-term investment. Am tempted to go for Draper Esprit but worried that one day IPO will finally surprise its long suffering shareholders on the upside.
bottomfisher
03/12/2020
09:17
There are some real gems in the p/f. It's worth a dig around on the co. website. Linked to Artois, Oxford Nanopore's [ONT] Twitter is well worth following, even if some of the tech is a bit much at times. Their market is rapidly broadening. Some of the listed flatliners in post one are stirring. DNL, MIRI, and TRX have all caught my eye. rambutan, I had a reply from Invesco, but they are not able to discuss with non account holders. I won't follow up, as you say, they are normally good at providing holdings rns. Obvious now there is a large buyer/s in the background. PS. Ip Group Plc hit an upwards yearly price breakout this morning.
bamboo2
03/12/2020
08:55
Very useful arrangement and uplift in value immediate, could be substantial if proceeds well.
p1nkfish
03/12/2020
08:27
Bamboo - thanks for that
benchmark
Chat Pages: Latest  81  80  79  78  77  76  75  74  73  72  71  70  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210418 09:50:12